Atossa Therapeutics (NASDAQ:ATOS) Upgraded at StockNews.com

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.

ATOS has been the subject of a number of other reports. HC Wainwright lifted their price objective on Atossa Therapeutics from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Atossa Therapeutics in a research report on Tuesday.

View Our Latest Stock Report on Atossa Therapeutics

Atossa Therapeutics Stock Performance

Shares of NASDAQ ATOS traded up $0.08 during midday trading on Tuesday, reaching $1.54. 1,430,852 shares of the company traded hands, compared to its average volume of 1,401,362. The firm has a market cap of $192.96 million, a PE ratio of -6.42 and a beta of 1.27. The stock’s 50-day simple moving average is $1.58 and its 200-day simple moving average is $1.10. Atossa Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.31.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last announced its earnings results on Monday, April 1st. The company reported ($0.06) earnings per share for the quarter. On average, equities research analysts expect that Atossa Therapeutics will post -0.28 EPS for the current year.

Insider Buying and Selling at Atossa Therapeutics

In related news, Director Jonathan Finn purchased 25,000 shares of the stock in a transaction on Wednesday, April 10th. The shares were purchased at an average price of $1.77 per share, with a total value of $44,250.00. Following the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at $44,250. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 7.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Atossa Therapeutics during the 3rd quarter worth approximately $98,000. Finally, PFG Investments LLC acquired a new position in shares of Atossa Therapeutics during the 1st quarter worth approximately $43,000. 12.74% of the stock is owned by institutional investors and hedge funds.

About Atossa Therapeutics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Recommended Stories

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.